DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Breast Cancer Female|Metastatic Triple-Negative Breast Carcinoma|ER Positive Breast Cancer|HER2-negative Breast Cancer|HER2 Negative Breast Carcinoma|ER-negative Breast Cancer
Interventions: DRUG: Datopotamab Deruxtecan
Sponsor: Sarah Sammons, MD
Collaborators: Daiichi Sankyo